Imperial College London


Faculty of MedicineNational Heart & Lung Institute

Research Associate



+44 (0)20 7594 7790jonathan.baker




223Guy Scadding BuildingRoyal Brompton Campus





Dr Jonathan Baker is a Research Associate at the Airway Disease Section of the National Heart and Lung Institute. His research interests involve investigating the accelerated ageing phenotype associated with the disease chronic obstructive pulmonary disease (COPD), understanding how cellular senescence may contribute to this phenotype .

Jonathan studied Biochemistry as an undergraduate at Newcastle University, where he was awarded the Emmerson Biochemistry Research prize for his dissertation. Following the completion of his studies in 2010 he continued his studies at Newcastle University, on obtaining his PhD in 2014. During his PhD he studied the role of a family of kinases, named Protein Kinase D, in the regulation of matrix metalloproteinase expression in osteoarthritis. This work was presented at the BSR in Birmingham, in which he was awarded their Young Investigator award.       

After completion of his PhD Jonathan started working for Professor Peter Barnes and Dr Kaz Ito at the NHLI. During this time Jonathan studyied the role of miRNAs in the regulation of sirtuin-1 and sirtuin-6, understanding the molecular mechanism which lead to the down-regulation of these putative anti-ageing proteins in patients with COPD. Presenting this work at both national and international conferences. Following on with this work, Jonathan began to work with Professor Louise Donnelly, focusing his work on understanding the mechanism which drive cellular senescence and the potential use of senolytics and senomorphic drugs in the treatment of COPD. 

Jonathan assists in the supervision of PhD, MRes, and BSc students and is a member of the American Thoracic Society, European Respiratory Society, and the British Association for Lung Research.



Perez E, Baker JR, Di Giandomenico S, et al., 2020, Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model., J Immunol, Vol:205, Pages:2489-2498

Alter P, Baker JR, Dauletbaev N, et al., 2020, Update in Chronic Obstructive Pulmonary Disease 2019, American Journal of Respiratory and Critical Care Medicine, Vol:202, ISSN:1073-449X, Pages:348-355

Baker JR, Donnelly LE, Barnes PJ, 2020, Senotherapy A New Horizon for COPD Therapy, Chest, Vol:158, ISSN:0012-3692, Pages:562-570

Fukuda Y, Akimoto K, Homma T, et al., 2020, Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach, Journal of Clinical Medicine, Vol:9

Tsilogianni Z, Baker JR, Papaporfyriou A, et al., 2020, Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?, Journal of Clinical Medicine, Vol:9

More Publications